



PRIOR AUTHORIZATION REQUEST

DIRECT RENIN INHIBITORS

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for **ALL PA requests**. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

1	Is this request for INITIAL or CONTINUATION of therapy with the requested medication?	
	<input type="checkbox"/> Initial (If checked, go to 7)	
	<input type="checkbox"/> Continuation (If checked, go to 2)	
2	Is the patient currently receiving the requested medication? [If no, skip to question 7.]	Yes No

If you have any questions, call:
1-888-258-8250

Version 03.2026

PRIOR AUTHORIZATION REQUEST

- | | | | |
|----|---|-----|----|
| 3 | Has the patient been receiving medication samples of the requested medication?
[If yes, skip to question 7.] | Yes | No |
| 4 | Does the patient have a previously approved prior authorization (PA) on file with the current plan?
[Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]
[If no, skip to question 7.] | Yes | No |
| 5 | Has the patient been established on therapy for at least 3 months?
[If no, skip to question 7.] | Yes | No |
| 6 | Has documentation been submitted to confirm that the patient has had a significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation.
[No further questions.] | Yes | No |
| 7 | What is the diagnosis or indication?

<input type="checkbox"/> Hypertension (HTN) (If checked, go to 8)

<input type="checkbox"/> Other (If checked, no further questions) | | |
| 8 | Is the patient 18 years of age or older?
[If no, no further questions.] | Yes | No |
| 9 | Has the patient experienced an inadequate response or inability to tolerate a trial of a formulary angiotensin receptor blocker (ARB) and angiotensin-converting enzyme (ACE) inhibitors?
[NOTE: The formulary angiotensin receptor blockers (ARBs) include: losartan, losartan/HCTZ, irbesartan, valsartan/HCTZ, candesartan, candesartan/HCTZ, valsartan, valsartan/HCTZ, amlodipine/valsartan; amlodipine/valsartan/HCTZ. The formulary angiotensin-converting enzyme (ACE) inhibitors include: lisinopril, lisinopril/HCTZ, benazepril, benazepril/HCTZ, captopril, captopril/HCTZ, enalapril, enalapril/HCTZ, fosinopril, fosinopril/HCTZ, quinapril, quinapril/HCTZ, ramipril, perindopril, amlodipine/benazepril, moexipril, moexipril/HCTZ, trandolapril.]
[If no, no further questions.] | Yes | No |
| 10 | Has the patient experienced an inadequate response or inability to tolerate AT LEAST ONE other formulary antihypertensive agent from a different therapeutic class: thiazide-type diuretic, calcium channel blocker, and beta-blocker?
[NOTE: Formulary thiazide-type diuretics include: chlorothiazide, Diuril, HCTZ, indapamide, methyclothiazide, metolazone. Formulary calcium channel blockers include: diltiazem, diltiazem ER, nifedipine, nifedipine ER, verapamil, verapamil ER, amlodipine, isradipine, nicardipine, nimodipine, felodipine ER, nisoldipine ER, Cartia XT, Taztia XT, Nifedical XL, Afeditab CR, Nifediac CC, Dilt-SR. Formulary | Yes | No |

**If you have any
questions, call:
1-888-258-8250**

Version 03.2026



PRIOR AUTHORIZATION REQUEST

beta-blockers include: atenolol, atenolol/chlorthalidone, bisoprolol, bisoprolol/HCTZ, carvedilol, metoprolol tartrate, metoprolol succinate, metoprolol/HCTZ, nadolol, nadolol/bendroflumethiazide, pindolol, propranolol, propranolol ER, propranolol/HCTZ, sotalol, sotalol (AF), timolol, acebutolol, betaxolol, labetalol.]

[If no, no further questions.]

- | | | | |
|----|---|-----|----|
| 11 | Is this medication being used in combination with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB)?
[If yes, no further questions.] | Yes | No |
| 12 | Does the requested dose exceed the Food and Drug Administration (FDA) approved label dosing for the requested indication? | Yes | No |

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

**If you have any questions, call:
1-888-258-8250**

Version 03.2026